HPP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hudson Pacific Properties Inc (HPP) is not a strong buy for a beginner investor with a long-term strategy at this time. While hedge funds are showing significant interest and the company has taken steps to stabilize its business, the financial performance remains weak with negative EPS and net income. Additionally, technical indicators and options data suggest a lack of immediate upward momentum. Given the investor's preference for long-term growth, it would be prudent to wait for clearer signs of recovery in the company's fundamentals and market sentiment before investing.
The technical indicators show a bearish trend with moving averages in a negative alignment (SMA_200 > SMA_20 > SMA_5). The RSI is neutral at 31.621, and the MACD is positive but contracting, indicating limited momentum. Key support is at 6.241, and resistance is at 7.002, suggesting the stock is trading near its support level.
Hedge funds are significantly increasing their positions in HPP, with a 1332.86% increase in buying over the last quarter. The company has taken targeted actions to stabilize its office performance and reduce NOI headwinds in the studio segment. Gross margin has improved significantly, up 969.23% YoY.
The company's financials remain weak, with a net income of -$277.92M and an EPS of -4.45, both reflecting significant losses. Analysts have been consistently lowering price targets, reflecting skepticism about the company's recovery. Options data shows bearish sentiment, and there is no recent positive news or congress trading activity to support the stock.
In Q4 2025, revenue increased by 22.11% YoY to $256.03M, but net income remained negative at -$277.92M, albeit improving by 66.42% YoY. EPS dropped by 46.26% YoY to -4.45. Gross margin improved significantly to 23.63%, up 969.23% YoY, but overall financial performance remains weak.
Analysts have mixed views, with Cantor Fitzgerald maintaining an Overweight rating but lowering the price target to $10. Other analysts, including Citi, Piper Sandler, and Morgan Stanley, have lowered price targets and maintain Neutral or Underweight ratings. The consensus reflects skepticism about the company's ability to recover in the near term.
